Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy

0346751 - ÚMG 2011 RIV GR eng J - Journal Article
Bubeník, Jan - Šímová, Jana
Genetically modified cellular vaccines against human papillomavirus type 16 (HPV16)-associated tumors: adjuvant treatment of minimal residual disease after surgery/chemotherapy.
Journal of Balkan Union of Oncology. Roč. 14, č. 1 (2009), s. 169-173. ISSN 1107-0625. E-ISSN 2241-6293
R&D Projects: GA ČR GA301/06/0774; GA ČR GA301/07/1410
EU Projects: European Commission(XE) 18933 - CLINIGENE
Institutional research plan: CEZ:AV0Z50520514
Keywords : residual tumour disease * HPV16 * cellular vaccines
Subject RIV: EB - Genetics ; Molecular Biology
Impact factor: 0.600, year: 2009

Local recurrences at the site of tumour resection or after chemotherapy, as well as distant micrometastases represent major problems in oncology. Genetically modified cellular vaccines were found to be efficient against cancer both in experimental models and in tumour-bearing patients. It was also shown in various systems that the efficacy of conventional therapeutic modalities can be supported by adjuvant administration of genetically modified vaccines, as well as by depletion of immunosuppressive immunocyte subsets. The purpose of this review is to summarize and evaluate the results obtained with administration of genetically modified cellular vaccines as well as with depletion of immunosuppressive immunocytes performed as treatment of the minimal residual tumour disease after surgery / chemotherapy in the experimental model of murine tumours mimicking human HPV 16-associated neoplasms. The prospects and limitations of these adjuvant immunotherapeutic modalities will be discussed.
Permanent Link: http://hdl.handle.net/11104/0187687